DaniLeigh's "FAMILY ONLY" Acquired by Music Licensing, Inc. (OTC: SONG)
June 17, 2024 09:20 ET
|
Music Licensing, Inc.
Naples, FL, June 17, 2024 (GLOBE NEWSWIRE) -- Music Licensing, Inc. (OTC: SONG), a premier company in the acquisition and management of music royalties, proudly announces the acquisition of...
DEADLINE ALERT for ASTS, DOCS, PERI, and SHCR: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
June 17, 2024 09:17 ET
|
The Law Offices of Frank R. Cruz
LOS ANGELES, June 17, 2024 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following...
Pineapple Interim CEO Adds Shares to His Position
June 17, 2024 09:15 ET
|
Pineapple Energy
Purchase by Pineapple Energy’s Interim CEO Affirms Commitment to Company’s Goals for Growth
DEADLINE NEXT WEEK: Berger Montague Advises Compass Minerals International (NYSE: CMP) Investors to Contact the Firm Before June 24, 2024
June 17, 2024 09:06 ET
|
Berger Montague
PHILADELPHIA, June 17, 2024 (GLOBE NEWSWIRE) -- Berger Montague announces that a class action lawsuit was filed in the U.S. District Court for the District of Kansas on behalf of those who acquired...
ARHT Media Announces Closing of Second and Final Tranche of Private Placement of Secured Subordinated Debentures
June 17, 2024 09:05 ET
|
ARHT Media Inc.
TORONTO, June 17, 2024 (GLOBE NEWSWIRE) -- ARHT Media Inc. ("ARHT" or the "Company") (TSXV:ART), (OTCQB:ARHTF) the global leader in the development, production and distribution of high-quality, low...
SELLAS Life Sciences Announces Positive Recommendation from the Independent Data Monitoring Committee of the Phase 3 REGAL Trial in Acute Myeloid Leukemia
June 17, 2024 09:05 ET
|
SELLAS Life Sciences Group, Inc.
– The Independent Data Monitoring Committee (IDMC) Recommends Continuation of Phase 3 REGAL Trial Without Any Modifications – – No Safety or Futility Concerns Were Raised Based on the Efficacy...
Digerati Technologies Reports Revenue of $7.430 Million for Third Quarter Fiscal Year 2024
June 17, 2024 09:00 ET
|
Digerati Technologies
- Non-GAAP Adjusted EBITDA – OPCO(1) of $0.784 Million – SAN ANTONIO, June 17, 2024 (GLOBE NEWSWIRE) -- Digerati Technologies, Inc. (OTCQB: DTGI) ("Digerati" or the "Company"), a provider of cloud...
Acute Myeloid Leukemia is on the Rise as Biotechs Race to Develop Groundbreaking Therapies
June 17, 2024 09:00 ET
|
FN Media Group LLC
PALM BEACH, Fla., June 17, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Acute Myeloid Leukemia (AML) is a type of cancer that affects the blood and bone marrow. It is characterized by...
iTeos und GSK starten Phase-III-Studie GALAXIES Lung-301 zur Untersuchung von Belrestotug und Dostarlimab bei zuvor unbehandeltem, inoperablem, lokal fortgeschrittenem/metastasiertem, PD-L1-selektiertem, nicht-kleinzelligem Lungenkrebs
June 17, 2024 09:00 ET
|
iTeos Therapeutics Inc.
WATERTOWN, Massachusetts, und GOSSELIES, Belgien, June 17, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS) („iTeos“), ein im klinischen Stadium tätiges Biopharmazie-Unternehmen, das...
Début de l’étude GALAXIES Lung-301 de Phase III à l’initiative conjointe d’iTeos et de GSK, visant à évaluer le doublet belrestotug + dostarlimab chez les patients atteints d’un cancer du poumon non à petites cellules PD-L1-positif, localement avancé ou métastatique, non résécable, non préalablement traité
June 17, 2024 09:00 ET
|
iTeos Therapeutics Inc.
WATERTOWN, État du Massachusetts et GOSSELIES, Belgique, 17 juin 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq : ITOS), ci-après « iTeos », une société biopharmaceutique au stade...